Abstract
Few studies have addressed the cost patterns of patients with multiple myeloma (MM) before and after first relapse. This US claims analysis evaluated, from a US health plan perspective, patterns of total direct costs of care from treatment initiation to progression for patients with MM treated with novel agents, using time to next therapy (TTNT) as a proxy measure for progression. A retrospective study was conducted using a large US claims database, evaluating patients with claims for MM between 2006 and 2013. Patients with claims for stem cell transplant (SCT) were excluded. The analysis focused on patients receiving lenalidomide (LEN) or bortezomib (BORT) based treatment, for whom complete claim history was available through initiation of subsequent treatment. Average patient monthly direct costs were determined, including medical and pharmacy costs, and total cost patterns over quarterly time periods were calculated. The study population comprised 2843 patients with newly diagnosed MM (NDMM) and 1361 with relapsed MM. Total monthly cost for patients with NDMM declined steadily, from $15,734 initially to $5082 at 18+ months after therapy. Upon initiation of second-line therapy, total monthly costs rose to $13,876 and declined...Continue Reading
References
Dec 6, 2003·The Oncologist·Robert C KaneRichard Pazdur
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Oct 9, 2008·Clinical Therapeutics·Ola GhatnekarMickael Löthgren
Feb 13, 2010·European Journal of Cancer Care·D KolevaL Garattini
May 28, 2010·Cancer Treatment Reviews·Brian G M Durie
Jan 5, 2011·Journal of Clinical Pharmacy and Therapeutics·X ArmoiryG Aulagner
Jan 29, 2011·Clinical Lymphoma, Myeloma & Leukemia·Jesús F San-MiguelDonna M Weber
Feb 19, 2011·American Journal of Epidemiology·Hude QuanVijaya Sundararajan
Mar 15, 2011·PharmacoEconomics·Andrea MessoriAlberto Bosi
Mar 31, 2011·Blood·Michele CavoUNKNOWN International Myeloma Working Group
Jan 25, 2012·Blood·Heinz LudwigUNKNOWN International Myeloma Working Group
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 15, 2012·Leukemia Research·Yuki KagoyaMineo Kurokawa
Nov 7, 2012·Journal of Clinical Pharmacy and Therapeutics·J G GaultneyC A Uyl-de Groot
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San MiguelPaul G Richardson
Jan 10, 2013·The Oncologist·April TeitelbaumHenry J Henk
Jan 10, 2013·The Oncologist·Jennifer G Gaultney, Carin A Uyl-de Groot
Oct 26, 2013·Leukemia·S K KumarS V Rajkumar
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboRobert Z Orlowski
Jul 26, 2014·Oncology·Miriam Y KimSikander Ailawadhi
Sep 4, 2014·The New England Journal of Medicine·Antonio PalumboMichele Cavo
Sep 4, 2014·The New England Journal of Medicine·Lotfi BenboubkerUNKNOWN FIRST Trial Team
Citations
Oct 31, 2015·Journal of Medical Economics·S Z UsmaniT Facon
Nov 12, 2016·Frontiers in Oncology·Nicole PrincicKathleen A Foley
Feb 22, 2017·Cancer·B Douglas SmithBrian G M Durie
May 10, 2017·Leukemia & Lymphoma·Amy E DeZernB Douglas Smith
Jul 25, 2017·Journal of Managed Care & Specialty Pharmacy·Ying ChenXianglin L Du
Dec 27, 2017·Journal of Medical Economics·Sebastian Gonzalez-McQuireLeah Fink
Sep 25, 2018·Journal of Managed Care & Specialty Pharmacy·David MerolaKenneth M Shermock
Aug 15, 2017·Leukemia & Lymphoma·Joanna P MacEwanClara Chen
Oct 19, 2019·Expert Review of Hematology·Tianqi XuGuangxun Gao
Oct 19, 2019·Future Oncology·Parameswaran HariKejal Parikh
Aug 8, 2019·Leukemia & Lymphoma·May HagiwaraRafael Fonseca
Jul 7, 2017·Oncology and Therapy·Steve ScheySujith Dhanasiri
Mar 28, 2019·Journal of Managed Care & Specialty Pharmacy·Sarah HollmannEric M Maiese
Aug 23, 2020·Cancers·Belinda A CampbellH Miles Prince
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Rafael Fonseca, Jennifer Hinkel
Oct 12, 2018·International Journal of Hematologic Oncology·John AshcroftChloe Middleton
Oct 17, 2018·PharmacoEconomics Open·Jill A BellDouglas V Faller
Jan 5, 2021·Journal of Medical Economics·Tilman Hans SteinmetzMonika Engelhardt
Feb 2, 2021·Future Oncology·Deepu MadduriAjai Chari
Feb 23, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Joshua RichterDrishti Shah
Mar 18, 2021·European Journal of Haematology·Fredrik BorgstenMagnus Björkholm
May 27, 2021·PloS One·Chih-Ning ChengFang-Ju Lin
Jun 15, 2021·Leukemia & Lymphoma·Elena ZamagniMurielle Roussel